Business context and reporting period
This summary covers the three months ended March 31, 2020. The supplied filing is for Unum Therapeutics Inc., not Cogent Biosciences, Inc.; verify that this is the intended filing. Unum was a development-stage biopharmaceutical company with no approved products or product sales. In March 2020, it shifted resources away from ACTR programs to its preclinical BOXR platform, prioritizing BOXR1030 for solid tumors.
Financial performance and liquidity
| Metric | Q1 2020 | Q1 2019 or comparison |
|---|---|---|
| Collaboration revenue | $7.0 million | $3.1 million |
| Research and development expense | $9.5 million | $12.4 million |
| General and administrative expense | $3.7 million | $2.5 million |
| Total operating expenses | $13.2 million | $14.9 million |
| Operating loss | $6.1 million | $11.8 million |
| Net loss | $6.1 million; $0.20 per share | $11.7 million; $0.39 per share |
| Operating cash used | $7.9 million | $11.5 million |
| Cash and cash equivalents at period end | $29.6 million | $37.4 million at Dec. 31, 2019 |
Revenue was collaboration revenue, not product sales. The quarter’s revenue included amounts associated with terminating the Seattle Genetics collaboration, including a $5.75 million termination payment and returned shares valued at approximately $0.8 million. Gross margin is not presented and is not a meaningful disclosed measure for this development-stage business.
At March 31, 2020, total assets were $38.9 million, total liabilities $13.2 million, and stockholders’ equity $25.7 million. The company reported no term-loan borrowings; up to $15 million was available under its Pacific Western Bank facility, although management said it did not plan to borrow. Cash, cash equivalents and restricted cash totaled $30.9 million. Management estimated existing cash would fund operations into mid-2021, but concluded substantial doubt existed about the company’s ability to continue as a going concern. No debt principal was outstanding under the facility.
Material changes versus the prior comparable period
- Revenue increased $4.0 million, principally reflecting recognition of Seattle Genetics collaboration amounts following termination of the agreement.
- Net loss narrowed by $5.6 million. R&D expense fell $2.9 million, mainly as hematologic programs were deprioritized; G&A increased $1.2 million, including restructuring-related personnel costs and advisory fees.
- Operating cash use decreased by $3.6 million year over year. Cash and cash equivalents declined $7.8 million from year-end 2019.
- In March, the company reduced its workforce by approximately 60% (43 employees) and recorded $1.7 million of restructuring charges; $0.6 million remained payable at quarter-end.
- Seattle Genetics terminated its collaboration effective January 16, 2020. It paid $5.75 million and returned 831,847 shares; Unum retained responsibility for winding down the ACTR-BCMA trial.
Outlook, risks, contingencies and unusual items
- Unum planned to advance preclinical BOXR1030, including IND-enabling work, and targeted an IND submission in late 2020. It expected to wind down ACTR clinical trials during 2020 and into early 2021. These are forward-looking plans, not assured outcomes.
- The company announced a strategic review to explore alternatives, with Ladenburg Thalmann as advisor; there was no assurance a transaction would be completed or benefit stockholders.
- Substantial doubt about going concern reflects recurring losses and operating cash outflows. The company said it would need additional financing or strategic arrangements; financing may be unavailable or dilutive, restrictive, or require relinquishing rights.
- Nasdaq had notified the company of a minimum-bid-price deficiency. The compliance period was tolled from April 16 and was scheduled to restart July 1, 2020, with a September 11, 2020 deadline to regain compliance; delisting or reduced trading liquidity remained risks.
- COVID-19 had not materially affected the financial statements through March 31, but could disrupt laboratory work, suppliers, clinical and regulatory timelines, and access to capital.
- After quarter-end, the company launched an employee option exchange, proposed a 1-for-5 to 1-for-10 reverse stock split subject to shareholder approval, and scheduled a shareholder vote for June 9, 2020. These events were not reflected in quarter-end share data.
- There were no material legal proceedings reported. The company stated disclosure controls were effective and reported no material change in internal control over financial reporting.
Most important facts for investors to verify
- Confirm the issuer identity: the filing is for Unum Therapeutics Inc., despite the request naming Cogent Biosciences, Inc.
- Assess whether cash runway into mid-2021 remains valid given operating burn, restructuring, trial wind-down costs, and the going-concern warning.
- Track progress toward the BOXR1030 IND target and whether COVID-19 or other development constraints change timing.
- Review the terms, actual use, and potential dilution of the LPC purchase agreement, the available bank facility, and other possible financing.
- Monitor the strategic review outcome, Nasdaq listing compliance, and the shareholder decision on the proposed reverse split.